Product allows medication to be inhaled deep into horses’ lungs.
The first inhaled treatment for severe equine asthma is now available in the UK and Ireland.
Manufactured by Boehringer Ingelheim, the Aservo® EquiHaler® marks more than a decade of collaboration between human pharma and Boehringer’s animal health business.
The inhaler incorporates Soft Mist Technology®, which is found in the Respimat® inhaler used in human respiratory disease. This allows the active ingredient to be inhaled deep into the horses’ lungs.
"It's another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation,” commented Dr Marc Laemmer, head of equine in UK & Ireland.
“We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo® EquiHaler® available. Our team of territory managers and vet advisers will conduct remote meetings with customers to make sure that they have the information and support they require.”
He continues: “The launch of Aservo® EquiHaler® is a prime example of leveraging innovation efforts of both our human and animal businesses. This has been a strength of ours and I'm excited that we are continuing to further increase the delivery of innovative solutions for horse owners and vets."
The active ingredient in the Aservo® EquiHaler® is ciclesonide - a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly associated with systemic corticosteroids.
It does not use a propellant, meaning that using the device does not contribute to harmful greenhouse gas emissions. It has also been manufactured from 50 per cent recycled materials.
Featuring an ergonomic handle, dosing lever, and nostril adapter, the Aservo® EquiHaler® has been awarded the prestigious Red Dot Award for Product Design.
The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.
